Trials / Completed
CompletedNCT04671290
Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae
Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae: a Multicenter Case-control Study.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 144 (actual)
- Sponsor
- Centre Hospitalier Annecy Genevois · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI.
Detailed description
Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were enrolled in a multicenter retrospective case-control study. Cases were treated with temocillin ≥50% of the effective antibiotic therapy duration. Control exclusively received carbapenem over the effective antibiotic therapy duration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Any intervention | No intervention |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2019-10-31
- Completion
- 2019-10-31
- First posted
- 2020-12-17
- Last updated
- 2020-12-17
Source: ClinicalTrials.gov record NCT04671290. Inclusion in this directory is not an endorsement.